<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252967</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00024771</org_study_id>
    <secondary_id>1137-2004</secondary_id>
    <nct_id>NCT00252967</nct_id>
  </id_info>
  <brief_title>Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)</brief_title>
  <official_title>Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether the drug, atorvastatin, will be able to reduce
      the rate of return of the abnormal beats after using cardioversion. Atorvastatin is a drug
      approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol but
      is not approved for preventing abnormal heartbeats. In addition to lowering cholesterol, the
      drug reduces inflammation. Inflammation seems to help cause atrial fibrillation, a certain
      type of abnormal heartbeat. In animals, atorvastatin reduces the risk of this type of
      abnormal beats, and preliminary data in humans supports an effect of atorvastatin and other
      similar drugs that have the same action on reducing the risk of this type of abnormal beats.
      We, the researchers at Emory University, would like to learn if this drug could prevent the
      return of these abnormal heartbeats.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) and its related disorder, atrial flutter (AFlut), are common
      abnormal heartbeats. Because they are similar and AFlut is rare compared to AF, they are
      usually treated similarly and discussed as one disorder. AF is an extremely common arrhythmia
      affecting more that 5% of the population over 65 years of age. It is an independent risk
      factor for death. AF is considered a progressive disease increasing in prevalence with age
      and converting from paroxysmal to permanent within a single individual. The projected
      lifetime risk of AF is 1 in 4 for men. AF occurs when there is an electrical short circuit in
      the top parts of the heart (atria). This causes the atria to beat at &gt;300 times per min in an
      irregular and ineffective manor. This has two consequences. The blood tends to pool in the
      atria allowing for clotting. Second, the bottom parts of the heart (ventricles) beat too
      rapidly in response to impulses arising in the atria. The rapid ventricular contraction
      without adequate filling time results in a reduced ejection of blood. This can cause heart
      failure symptoms such as shortness of breath and reduced blood flow to organs resulting in
      lightheadedness or collapse.

      One logical therapy to correct the defects arising from AF is return the abnormal heartbeats
      back to the normal rhythm. This can be done with electrical shock therapy (cardioversion) or
      by drugs called antiarrhythmic agents. Often, they are used together. While its stands to
      reason that using these techniques to restore rhythm to normal would be beneficial, clinical
      trials show that leaving patients in AF and thinning the blood to prevent blood clots is
      equally efficacious to trying to restore normal beating (sinus rhythm). The common
      explanations for this are that AF returns rapidly despite antiarrhythmic drugs and that
      antiarrhythmic drugs can make worse abnormal heart beats, a phenomenon known as
      proarrhythmia.

      Based on the lack of efficacy of current therapies and similarities between risk factors for
      atherosclerosis (hardening of the arteries) and AF, we began to investigate whether oxidative
      stress, a mechanism similar to inflammation thought to be responsible for atherosclerosis,
      might be playing a role in causing AF. We studied this in pigs first and found that when we
      put pigs into AF, they had a large increase in oxidative stress markers. Then, we made a
      mouse that had too much oxidative stress in the heart, and this mouse developed AF. Based on
      this and other data in humans, we hypothesized that oxidative stress can cause AF.

      Atorvastatin is a cholesterol lowering medication that works by blocking production of
      cholesterol at an early stage. This has the effect of preventing the synthesis of molecules
      required to assemble the most common enzymatic source of oxidative stress, the NADPH oxidase.
      Therefore, atorvastatin decreases oxidative stress in addition to reducing cholesterol, and
      if our hypothesis is correct, atorvastatin should reduce the incidence of AF.

      In this study we chose to look at patients undergoing cardioversion. This is because this
      group has a high likelihood of recurrence of AF and would benefit most by an effective drug.
      Once the decision is made to have the patient undergo cardioversion, we will approach the
      patient about enrolling in this trial. The only change in their medical therapy will be the
      addition of the study drug. The study requires no other alterations to the standard of care.
      If patients agree to participate, then they will be started on the study drug and followed
      for recurrence of AF by a variety of surface electrocardiogram techniques. All of which are
      noninvasive. To insure the medicine is not causing side effects, examinations and blood tests
      will be done, and to study whether the drug actually affects oxidative stress, blood will be
      analyzed. The subjects participation ends when AF recurs or after 1 year. This will be a
      double blind, placebo controlled trial and will be analyzed on an intention to treat basis.

      The risks of this study to the patient are likely to be small compared to the potential
      benefit of reduced AF burden. Based on a previous trial using the same dose of study
      medication, the risks of all study drug related adverse events is likely to be &lt;3%. All of
      these are expected to be reversible with discontinuation of the drug.

      The significance of this research is that currently treatments to address AF are less than
      optimal. Antiarrhythmic drugs are variably effective and are associated with potentially
      lethal proarrhythmic side effects. The common treatment to prevent strokes in subjects with
      AF is chronic warfarin administration, but warfarin therapy requires frequent monitoring and
      adjustment of dose and is associated with bleeding complications. This research may provide
      the first new therapeutic strategy in many years for AF and the most serious consequence of
      AF, stroke.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient power to show therapy difference at interim analysis.
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of Atrial Fibrillation Recurrence</measure>
    <time_frame>Upon recurrence, up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Redox Potential for Cysteine Values</measure>
    <time_frame>Baseline and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Redox Potential for Glutathione Values</measure>
    <time_frame>Baseline and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Derivatives of Reactive Oxygen Metabolites Values</measure>
    <time_frame>Baseline and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Isoprostanes Values</measure>
    <time_frame>Baseline and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Interleukin-6 Values</measure>
    <time_frame>Baseline and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Interleukin-1 Values</measure>
    <time_frame>Baseline and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of High Sensitivity C-reactive Protein</measure>
    <time_frame>Baseline and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Tumor Necrosis Factor Alpha Values</measure>
    <time_frame>Baseline and 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin at a dose of 80 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80 mg of Atorvastatin</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; or = 18 years of age

          -  Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG
             documentation)

          -  Able to swallow pill form of drug

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  enrollment in another ongoing trial

          -  paroxysmal atrial fibrillation

          -  hemodynamic instability

          -  atrial fibrillation ablation within 6 months of enrollment

          -  a contraindication for anticoagulation

          -  severe valvular heart disease

          -  presence of single lead implantable cardioverter defibrillator

          -  unstable angina

          -  New York Heart Association (NYHA) Class IV heart failure

          -  hyperthyroidism

          -  uncontrolled hypertension (blood pressure &gt; 180/100 at rest) on medications

          -  an illness that would limit life expectancy to less than 1 year

          -  use of statins within the previous 30 days

          -  significant coronary artery disease or lipid abnormalities necessitating statin
             therapy

          -  implanted devices for active management of arrhythmias by pacing or defibrillation

          -  lack of access to a telephone

          -  illicit drug use

          -  alcohol abuse

          -  hypersensitivity to atorvastatin by history

          -  pregnancy

          -  sexually active female subjects not on contraception or surgically sterilized

          -  nursing mothers

          -  chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the
             upper limit of normal [ULN] of laboratory reference range)

          -  severe renal disease (creatinine &gt; 200 mmol/L)

          -  inflammatory muscle disease or creatine kinase (CK) &gt; 3 times ULN

          -  concurrent treatment with cyclosporine, fibrates, or high-dose niacin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel D. Dudley, Jr., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Administration Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veteran Administration Medical Center/Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crawford Long Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Negi, S., Shukrullah, I., Veladar, E., Bloom, H., Jones, D., S.C. Dudley, Jr. (2010). Statin Therapy for Prevention of Atrial Fibrillation Trial (SToP AF trial). [Abstract]. ACC 2010. 10-A-11608-ACC.</citation>
  </results_reference>
  <results_reference>
    <citation>Negi S, Shukrullah I, Veledar E, Bloom HL, Jones DP, Dudley SC. Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol. 2011 Apr;22(4):414-9. doi: 10.1111/j.1540-8167.2010.01925.x. Epub 2010 Oct 13.</citation>
    <PMID>20946227</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <results_first_submitted>April 21, 2014</results_first_submitted>
  <results_first_submitted_qc>August 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 3, 2014</results_first_posted>
  <last_update_submitted>August 21, 2014</last_update_submitted>
  <last_update_submitted_qc>August 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Samuel C. Dudley, Jr.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Reactive Oxgen Speers</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>Atorvastatin</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Atorvastatin</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="13.9"/>
                    <measurement group_id="B2" value="58.2" spread="11.6"/>
                    <measurement group_id="B3" value="58.5" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time of Atrial Fibrillation Recurrence</title>
        <time_frame>Upon recurrence, up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
          </group>
        </group_list>
        <measure>
          <title>Time of Atrial Fibrillation Recurrence</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="7" upper_limit="70"/>
                    <measurement group_id="O2" value="29" lower_limit="2" upper_limit="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Redox Potential for Cysteine Values</title>
        <time_frame>Baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Redox Potential for Cysteine Values</title>
          <units>mV</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.2" lower_limit="-71.2" upper_limit="-54.8"/>
                    <measurement group_id="O2" value="-65.3" lower_limit="-71.3" upper_limit="-58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (30 day follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.5" lower_limit="-69.8" upper_limit="-58.5"/>
                    <measurement group_id="O2" value="-62.6" lower_limit="-68.0" upper_limit="-58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Redox Potential for Glutathione Values</title>
        <time_frame>Baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Redox Potential for Glutathione Values</title>
          <units>mV</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-116.7" lower_limit="-134.9" upper_limit="-110.2"/>
                    <measurement group_id="O2" value="-125.3" lower_limit="-138.0" upper_limit="-117.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (30 day follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-124.3" lower_limit="-142.1" upper_limit="-109.0"/>
                    <measurement group_id="O2" value="-129.0" lower_limit="-138.2" upper_limit="-113.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Derivatives of Reactive Oxygen Metabolites Values</title>
        <time_frame>Baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Derivatives of Reactive Oxygen Metabolites Values</title>
          <units>Carr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384" lower_limit="276" upper_limit="422"/>
                    <measurement group_id="O2" value="382" lower_limit="322" upper_limit="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (30 day follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400" lower_limit="338" upper_limit="450"/>
                    <measurement group_id="O2" value="345" lower_limit="304" upper_limit="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Isoprostanes Values</title>
        <time_frame>Baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Isoprostanes Values</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1259" lower_limit="1040" upper_limit="1738"/>
                    <measurement group_id="O2" value="1062" lower_limit="817" upper_limit="1421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (30 day follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1146" lower_limit="964" upper_limit="1397"/>
                    <measurement group_id="O2" value="1240" lower_limit="953" upper_limit="1397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Interleukin-6 Values</title>
        <time_frame>Baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Interleukin-6 Values</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="2.1" upper_limit="9.2"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.7" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (30 day follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.2" upper_limit="8.6"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.7" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Interleukin-1 Values</title>
        <time_frame>Baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Interleukin-1 Values</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.20" upper_limit="0.44"/>
                    <measurement group_id="O2" value="0.30" lower_limit="0.17" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (30 day follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.17" upper_limit="0.32"/>
                    <measurement group_id="O2" value="0.28" lower_limit="0.21" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of High Sensitivity C-reactive Protein</title>
        <time_frame>Baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of High Sensitivity C-reactive Protein</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="1.7" upper_limit="15.0"/>
                    <measurement group_id="O2" value="6.3" lower_limit="2.2" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (30 day follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="2.8" upper_limit="14.4"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.3" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Tumor Necrosis Factor Alpha Values</title>
        <time_frame>Baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Tumor Necrosis Factor Alpha Values</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.2" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.4" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month (30 day follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.7" upper_limit="3.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.2" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Atorvastatin</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited enrollment; recurrence rate of AF was slightly higher than other trials indicated that the study sample may be a high-risk population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Samuel Dudley, MD, PhD</name_or_title>
      <organization>Brown University</organization>
      <phone>4014443024</phone>
      <email>samuel_dudley@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

